<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>WASHINGTON, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM 8-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CURRENT REPORT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Date of Report (date of earliest event reported):
<B>October 25, 2012</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Synthetic Biologics, Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Exact name of registrant as specified in
charter)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Nevada</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(State or other jurisdiction of incorporation)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; font-size: 10pt; font-weight: bold; text-align: center"><B>01-12584</B></TD>
    <TD STYLE="width: 50%; font-size: 10pt; font-weight: bold; text-align: center"><B>13-3808303</B></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; text-align: center">(Commission File Number)</TD>
    <TD STYLE="font-size: 10pt; text-align: center">(IRS Employer Identification No.)</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>617 Detroit Street, Suite 100</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Ann Arbor, MI 4810</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="text-align: center; margin-left: 0; margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 50%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;(Address of principal executive offices
and zip code)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(734) 332-7800</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 50%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;(Registrant&rsquo;s telephone number
including area code)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>N/A</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 50%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Former Name and Former Address)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Check the appropriate box below if the Form
8-K filing is intended to simultaneously satisfy the filing obligation of registrant under any of the following provisions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 6%">&nbsp;</TD>
    <TD STYLE="width: 6%; font-family: Wingdings">&uml;</TD>
    <TD STYLE="width: 88%">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 6%">&nbsp;</TD>
    <TD STYLE="width: 6%; font-family: Wingdings">&uml;</TD>
    <TD STYLE="width: 88%">Soliciting material pursuant to Rule 14a-12(b) under the Exchange Act (17 CFR 240.14a-12)</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 6%">&nbsp;</TD>
    <TD STYLE="width: 6%; font-family: Wingdings">&uml;</TD>
    <TD STYLE="width: 88%">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 6%">&nbsp;</TD>
    <TD STYLE="width: 6%; font-family: Wingdings">&uml;</TD>
    <TD STYLE="width: 88%; text-align: justify">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;&nbsp;</B></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Item 1.01 Entry into a Material Definitive Agreement.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On October 25, 2012, Synthetic Biologics, Inc. (the &ldquo;Company&rdquo;)
entered into a Stock Purchase Agreement (the &ldquo;Purchase Agreement&rdquo;) with certain accredited investors (the &ldquo;Purchasers&rdquo;),
pursuant to which the Company agreed to sell to the Purchasers in a private placement an aggregate of 6,750,000 shares of the Company&rsquo;s
Common Stock at a price per share of $1.60 (the &ldquo;Common Shares&rdquo;) for aggregate gross proceeds of $10,800,000 (the &ldquo;Offering&rdquo;).
On October 30, 2012, the Company completed the Offering. T<FONT STYLE="color: black">he Company intends to use the net proceeds
from the Offering to develop its monoclonal antibody and synthetic DNA programs through its Exclusive Channel Collaborations with
Intrexon Corporation, and for general corporate purposes, including the execution of its business plan and expansion of its pipeline.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In connection with the Offering, the Company also entered into
a registration rights agreement with certain of the Purchasers (the &ldquo;Registration Rights Agreement&rdquo;). The Registration
Rights Agreement requires that the Company file a registration statement (the &ldquo;Initial Registration Statement&rdquo;) with
the Securities and Exchange Commission (the &ldquo;SEC&rdquo;) within forty-five (45) days of the closing date of the Offering
(the &ldquo;Filing Date&rdquo;) for the resale by the Purchasers of all of the Common Shares owned by such Purchasers and all shares
of Common Stock issuable upon any stock split, dividend or other distribution, recapitalization or similar event with respect thereto
(the &ldquo;Registrable Securities&rdquo;). The Initial Registration Statement must be declared effective by the SEC within ninety
(90)&nbsp;days of the closing date of the Offering (the &ldquo;Effectiveness Date&rdquo;) subject to certain adjustments. Upon
the occurrence of certain events (each an &ldquo;Event&rdquo;), including, but not limited to, that the Initial Registration Statement
is not filed prior to the Filing Date, the Company will be required to pay to each of the Purchasers liquidated damages of 1.5%
of their aggregate purchase price upon the date of the Event and then monthly thereafter until the&nbsp;Event is cured. In no event
will the aggregate amount of liquidated damages payable to each of the Purchasers exceed in the aggregate 10% of the aggregate
purchase price paid by such Purchaser for the Registrable Securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In connection with the Offering, the Company also entered into
an agreement with a certain Purchaser that is an affiliate of Intrexon Corporation (the &ldquo;Joinder Agreement&rdquo;) pursuant
to which such Purchaser agreed to be bound by the terms of and join Intrexon Corporation as a party to its registration rights
agreement with the Company entered into in connection with the Exclusive Channel Collaboration Agreement between the Company and
Intrexon Corporation dated August 6, 2012.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Griffin Securities, Inc. (the &ldquo;Placement Agent&rdquo;)
served as the placement agent for the Offering. In consideration for services rendered as the Placement Agent in the Offering,
the Company agreed to (i) pay to the Placement Agent cash commissions equal to 6.0% of the gross proceeds received in the Offering,
(ii) issue to the Placement Agent, or its designee, a five-year warrant to purchase up to 635,855 shares of the Company&rsquo;s
Common Stock with an exercise price of $1.60 per share (the &ldquo;Placement Agent Warrant&rdquo;) and (iii) reimburse the Placement
Agent for its reasonable actual out-of-pocket expenses incurred in connection with the Offering, including reasonable legal fees
and disbursements. The Placement Agent Warrant also provides for the same registration rights and obligations, and is subject to
certain limitations, as set forth in the Registration Rights Agreement with respect to the Common Shares underlying such warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The foregoing descriptions of the Purchase Agreement, Registration
Rights Agreement, Joinder Agreement, and Placement Agent Warrant (collectively, the &ldquo;Transaction Documents&rdquo;) do not
purport to be complete and are qualified in their entireties by reference to the full text of the Purchase Agreement, Registration
Rights Agreement, Joinder Agreement, and form of Placement Agent Warrant, which are filed as Exhibit 10.1, Exhibit 10.2, Exhibit
10.3, and Exhibit 10.4, respectively, to this Current Report on Form 8-K and incorporated herein by reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On October 31, 2012, the Company issued the press release attached
hereto as Exhibit 99.1 regarding the Offering described herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><U>Important Notice regarding the Transaction Documents</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Transaction Documents have been included as exhibits to
this Form 8-K to provide investors and security holders with information regarding their terms. They are not intended to provide
any other financial information about the Company or its subsidiaries. The representations, warranties and covenants contained
in the Transaction Documents were made only for purposes of those agreements and as of specific dates; were solely for the benefit
of the parties to the Transaction Documents; may be subject to limitations agreed upon by the parties, including being qualified
by disclosures made for the purposes of allocating contractual risk between the parties to the Transaction Documents instead of
establishing these matters as facts; and may be subject to standards of materiality applicable to the contracting parties that
differ from those applicable to investors. Investors should not rely on the representations, warranties and covenants or any description
thereof as characterizations of the actual state of facts or condition of the Company. Moreover, information concerning the subject
matter of the representations, warranties and covenants may change after the date of the Transaction Documents, which subsequent
information may or may not be fully reflected in public disclosures by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 12%; font-size: 10pt; font-weight: bold"><B>Item 3.02</B></TD>
    <TD STYLE="width: 88%; font-size: 10pt; font-weight: bold"><B>Unregistered Sales of Equity Securities.</B></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The information contained in Item 1.01 is hereby incorporated
by reference. Pursuant to the Offering, on October 30, 2012, the Company offered and sold the Common Shares to the Purchasers who
represented that each was an &ldquo;accredited investor&rdquo; as such term is defined in the Securities Act of 1933,as amended
(the &ldquo;Securities Act&rdquo;) in reliance on the exemption from registration afforded by Section 4(2) and Regulation D (Rule
506) under the Securities Act and corresponding provisions of state securities laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Placement Agent Warrant (including the shares of the Company&rsquo;s
Common Stock underlying such warrant) was offered and sold to the Placement Agent in reliance on the exemption from registration
afforded by Section 4(2) of the Securities Act and corresponding provisions of state securities laws. The Placement Agent represented
that it was an &ldquo;accredited investor&rdquo; as such term is defined in the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Accordingly, the Common Shares issued in the Offering and the
Placement Agent Warrant (including the shares of the Company&rsquo;s Common Stock underlying such warrant) have not been registered
under the Securities Act, and until registered, these securities may not be offered or sold in the United States absent registration
or availability of an applicable exemption from registration. Neither this Current Report on Form 8-K, nor the exhibits attached
hereto is an offer to sell or the solicitation of an offer to buy securities of the Company.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD COLSPAN="3" STYLE="font-weight: bold"><B>Item 9.01</B></TD>
    <TD STYLE="font-weight: bold"><B>Financial Statements and Exhibits.</B></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>(d)</TD>
    <TD COLSPAN="2">Exhibits</TD></TR>
<TR>
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 6%">&nbsp;</TD>
    <TD STYLE="width: 88%">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 10%; border-bottom: black 1pt solid; font-weight: bold"><B>Exhibit No.</B></TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 88%; border-bottom: black 1pt solid; font-weight: bold"><B>Description</B></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">10.1</TD>
    <TD>&nbsp;</TD>
    <TD>Form of Stock Purchase Agreement dated October 25, 2012.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">10.2</TD>
    <TD>&nbsp;</TD>
    <TD>Form of Registration Rights Agreement dated October 25, 2012.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">10.3</TD>
    <TD>&nbsp;</TD>
    <TD>Joinder Agreement dated October 25, 2012.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">10.4</TD>
    <TD>&nbsp;</TD>
    <TD>Form of Placement Agent Warrant dated October 30, 2012.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">99.1</TD>
    <TD>&nbsp;</TD>
    <TD>Press Release dated October 31, 2012.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>SIGNATURES</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Pursuant to the requirements of the Securities Exchange Act
of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD>Dated: October 31, 2012</TD>
    <TD COLSPAN="2">SYNTHETIC BIOLOGICS, INC.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">(Registrant)</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 51%">&nbsp;</TD>
    <TD STYLE="width: 4%">&nbsp;</TD>
    <TD STYLE="width: 45%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>By:</TD>
    <TD STYLE="border-bottom: Black 1pt solid">/s/ C. Evan Ballantyne</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">Name: C. Evan Ballantyne</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">Title: Chief Financial Officer</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>INDEX OF EXHIBITS</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 13%; border-bottom: black 1pt solid; font-weight: bold"><B>Exhibit No.</B></TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 85%; border-bottom: black 1pt solid; font-weight: bold"><B>Description</B></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">10.1</TD>
    <TD>&nbsp;</TD>
    <TD>Form of Stock Purchase Agreement dated October 25, 2012.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">10.2</TD>
    <TD>&nbsp;</TD>
    <TD>Form of Registration Rights Agreement dated October 25, 2012.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">10.3</TD>
    <TD>&nbsp;</TD>
    <TD>Joinder Agreement dated October 25, 2012.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">10.4</TD>
    <TD>&nbsp;</TD>
    <TD>Form of Placement Agent Warrant dated October 30, 2012.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">99.1</TD>
    <TD>&nbsp;</TD>
    <TD>Press Release dated October 31, 2012.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 5; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
[{"type": "8-K", "sequence": "1", "filename": "v326949_8k.htm", "description": "FORM 8-K", "secsgml_size_bytes": 27576}]
{"company-data": {"conformed-name": "Synthetic Biologics, Inc.", "cik": "0000894158", "assigned-sic": "2834", "irs-number": "133808303", "state-of-incorporation": "NV", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "001-12584", "film-number": "121170342"}, "business-address": {"street1": "3985 RESEARCH PARK DRIVE,", "street2": "SUITE 200", "city": "ANN ARBOR", "state": "MI", "zip": "48108", "phone": "(734) 332-7800"}, "mail-address": {"street1": "3985 RESEARCH PARK DRIVE,", "street2": "SUITE 200", "city": "ANN ARBOR", "state": "MI", "zip": "48108"}, "former-company": [{"former-conformed-name": "ADEONA PHARMACEUTICALS, INC.", "date-changed": "20081027"}, {"former-conformed-name": "PIPEX PHARMACEUTICALS, INC.", "date-changed": "20061214"}, {"former-conformed-name": "SHEFFIELD PHARMACEUTICALS INC", "date-changed": "19970730"}]}
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (date of earliest event reported):
October 25, 2012
Synthetic Biologics, Inc.
(Exact name of registrant as specified in
charter)
Nevada
(State or other jurisdiction of incorporation)
01-12584
13-3808303
(Commission File Number)
(IRS Employer Identification No.)
617 Detroit Street, Suite 100
Ann Arbor, MI 4810
(Address of principal executive offices
and zip code)
(734) 332-7800
(Registrant's telephone number
including area code)
N/A
(Former Name and Former Address)
Check the appropriate box below if the Form
8-K filing is intended to simultaneously satisfy the filing obligation of registrant under any of the following provisions:
¨
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨
Soliciting material pursuant to Rule 14a-12(b) under the Exchange Act (17 CFR 240.14a-12)
¨
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 1.01 Entry into a Material Definitive Agreement.
On October 25, 2012, Synthetic Biologics, Inc. (the "Company")
entered into a Stock Purchase Agreement (the "Purchase Agreement") with certain accredited investors (the "Purchasers"),
pursuant to which the Company agreed to sell to the Purchasers in a private placement an aggregate of 6,750,000 shares of the Company's
Common Stock at a price per share of $1.60 (the "Common Shares") for aggregate gross proceeds of $10,800,000 (the "Offering").
On October 30, 2012, the Company completed the Offering. T
he Company intends to use the net proceeds
from the Offering to develop its monoclonal antibody and synthetic DNA programs through its Exclusive Channel Collaborations with
Intrexon Corporation, and for general corporate purposes, including the execution of its business plan and expansion of its pipeline.
In connection with the Offering, the Company also entered into
a registration rights agreement with certain of the Purchasers (the "Registration Rights Agreement"). The Registration
Rights Agreement requires that the Company file a registration statement (the "Initial Registration Statement") with
the Securities and Exchange Commission (the "SEC") within forty-five (45) days of the closing date of the Offering
(the "Filing Date") for the resale by the Purchasers of all of the Common Shares owned by such Purchasers and all shares
of Common Stock issuable upon any stock split, dividend or other distribution, recapitalization or similar event with respect thereto
(the "Registrable Securities"). The Initial Registration Statement must be declared effective by the SEC within ninety
(90) days of the closing date of the Offering (the "Effectiveness Date") subject to certain adjustments. Upon
the occurrence of certain events (each an "Event"), including, but not limited to, that the Initial Registration Statement
is not filed prior to the Filing Date, the Company will be required to pay to each of the Purchasers liquidated damages of 1.5%
of their aggregate purchase price upon the date of the Event and then monthly thereafter until the Event is cured. In no event
will the aggregate amount of liquidated damages payable to each of the Purchasers exceed in the aggregate 10% of the aggregate
purchase price paid by such Purchaser for the Registrable Securities.
In connection with the Offering, the Company also entered into
an agreement with a certain Purchaser that is an affiliate of Intrexon Corporation (the "Joinder Agreement") pursuant
to which such Purchaser agreed to be bound by the terms of and join Intrexon Corporation as a party to its registration rights
agreement with the Company entered into in connection with the Exclusive Channel Collaboration Agreement between the Company and
Intrexon Corporation dated August 6, 2012.
Griffin Securities, Inc. (the "Placement Agent")
served as the placement agent for the Offering. In consideration for services rendered as the Placement Agent in the Offering,
the Company agreed to (i) pay to the Placement Agent cash commissions equal to 6.0% of the gross proceeds received in the Offering,
(ii) issue to the Placement Agent, or its designee, a five-year warrant to purchase up to 635,855 shares of the Company's
Common Stock with an exercise price of $1.60 per share (the "Placement Agent Warrant") and (iii) reimburse the Placement
Agent for its reasonable actual out-of-pocket expenses incurred in connection with the Offering, including reasonable legal fees
and disbursements. The Placement Agent Warrant also provides for the same registration rights and obligations, and is subject to
certain limitations, as set forth in the Registration Rights Agreement with respect to the Common Shares underlying such warrant.
The foregoing descriptions of the Purchase Agreement, Registration
Rights Agreement, Joinder Agreement, and Placement Agent Warrant (collectively, the "Transaction Documents") do not
purport to be complete and are qualified in their entireties by reference to the full text of the Purchase Agreement, Registration
Rights Agreement, Joinder Agreement, and form of Placement Agent Warrant, which are filed as Exhibit 10.1, Exhibit 10.2, Exhibit
10.3, and Exhibit 10.4, respectively, to this Current Report on Form 8-K and incorporated herein by reference.
On October 31, 2012, the Company issued the press release attached
hereto as Exhibit 99.1 regarding the Offering described herein.
Important Notice regarding the Transaction Documents
The Transaction Documents have been included as exhibits to
this Form 8-K to provide investors and security holders with information regarding their terms. They are not intended to provide
any other financial information about the Company or its subsidiaries. The representations, warranties and covenants contained
in the Transaction Documents were made only for purposes of those agreements and as of specific dates; were solely for the benefit
of the parties to the Transaction Documents; may be subject to limitations agreed upon by the parties, including being qualified
by disclosures made for the purposes of allocating contractual risk between the parties to the Transaction Documents instead of
establishing these matters as facts; and may be subject to standards of materiality applicable to the contracting parties that
differ from those applicable to investors. Investors should not rely on the representations, warranties and covenants or any description
thereof as characterizations of the actual state of facts or condition of the Company. Moreover, information concerning the subject
matter of the representations, warranties and covenants may change after the date of the Transaction Documents, which subsequent
information may or may not be fully reflected in public disclosures by the Company.
Item 3.02
Unregistered Sales of Equity Securities.
The information contained in Item 1.01 is hereby incorporated
by reference. Pursuant to the Offering, on October 30, 2012, the Company offered and sold the Common Shares to the Purchasers who
represented that each was an "accredited investor" as such term is defined in the Securities Act of 1933,as amended
(the "Securities Act") in reliance on the exemption from registration afforded by Section 4(2) and Regulation D (Rule
506) under the Securities Act and corresponding provisions of state securities laws.
The Placement Agent Warrant (including the shares of the Company's
Common Stock underlying such warrant) was offered and sold to the Placement Agent in reliance on the exemption from registration
afforded by Section 4(2) of the Securities Act and corresponding provisions of state securities laws. The Placement Agent represented
that it was an "accredited investor" as such term is defined in the Securities Act.
Accordingly, the Common Shares issued in the Offering and the
Placement Agent Warrant (including the shares of the Company's Common Stock underlying such warrant) have not been registered
under the Securities Act, and until registered, these securities may not be offered or sold in the United States absent registration
or availability of an applicable exemption from registration. Neither this Current Report on Form 8-K, nor the exhibits attached
hereto is an offer to sell or the solicitation of an offer to buy securities of the Company.
Item 9.01
Financial Statements and Exhibits.
(d)
Exhibits
Exhibit No.
Description
10.1
Form of Stock Purchase Agreement dated October 25, 2012.
10.2
Form of Registration Rights Agreement dated October 25, 2012.
10.3
Joinder Agreement dated October 25, 2012.
10.4
Form of Placement Agent Warrant dated October 30, 2012.
99.1
Press Release dated October 31, 2012.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act
of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: October 31, 2012
SYNTHETIC BIOLOGICS, INC.
(Registrant)
By:
/s/ C. Evan Ballantyne
Name: C. Evan Ballantyne
Title: Chief Financial Officer
INDEX OF EXHIBITS
Exhibit No.
Description
10.1
Form of Stock Purchase Agreement dated October 25, 2012.
10.2
Form of Registration Rights Agreement dated October 25, 2012.
10.3
Joinder Agreement dated October 25, 2012.
10.4
Form of Placement Agent Warrant dated October 30, 2012.
99.1
Press Release dated October 31, 2012.